Investor Presentation Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Investor Presentation BSE India FY26 Earnings Call Investor Presentation
Investor Presentation Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Investor Presentation BSE India Investor Presentation on Q3 earning for FY 2025-26
Investor Presentation Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Investor Presentation BSE India Investor Presentation on the Financial Results for the quarter and half year ended 30th September, 2025
Investor Presentation Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Investor Presentation BSE India Earnings Call Presentation for the quarter ended 30th June, 2025
Investor Presentation Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Investor Presentation BSE India Investor Presentation on Proposed Investment.
Investor Presentation Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Investor Presentation BSE India Earnings Presentation for the quarter and year ended 31st March, 2025
Investor Presentation NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Investor Presentation BSE India Q3 FY25 Earnings Presentation
Investor Presentation NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Investor Presentation BSE India Investor Presentation for the quarter and half year ended 30th September, 2024
Investor Presentation NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Investor Presentation BSE India Investor Presentation for the quarter ended 30th June, 2024
Investor Presentation NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Investor Presentation BSE India Investor Presentation